Profile data is unavailable for this security.
About the company
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
- Revenue in USD (TTM)81.00k
- Net income in USD-48.82m
- Incorporated2013
- Employees49.00
- LocationActinium Pharmaceuticals Inc100 Park Ave., 23Rd FloorNEW YORK 10017United StatesUSA
- Phone+1 (646) 677-3870
- Fax+1 (845) 818-3588
- Websitehttps://www.actiniumpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Generation Bio Co | 5.90m | -126.61m | 198.77m | 174.00 | -- | 0.9745 | -- | 33.67 | -1.97 | -1.97 | 0.0916 | 3.07 | 0.0157 | -- | 2.71 | 33,931.04 | -33.72 | -36.96 | -36.60 | -39.21 | -- | -- | -2,144.51 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| INmune Bio Inc | 155.00k | -30.01m | 199.39m | 11.00 | -- | 5.00 | -- | 1,286.39 | -1.67 | -1.67 | 0.0086 | 2.12 | 0.0022 | -- | 0.0284 | 14,090.91 | -43.24 | -37.82 | -54.85 | -41.86 | -- | -- | -19,360.00 | -14,901.03 | -- | -13.06 | 0.2064 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Poseida Therapeutics Inc | 64.70m | -123.43m | 199.73m | 330.00 | -- | 1.91 | -- | 3.09 | -1.38 | -1.38 | 0.7175 | 1.08 | 0.2068 | -- | 7.15 | 196,069.70 | -39.45 | -40.70 | -49.32 | -47.72 | -- | -- | -190.76 | -233.49 | -- | -14.93 | 0.361 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| Compass Therapeutics Inc. | 0.00 | -42.49m | 203.63m | 32.00 | -- | 1.27 | -- | -- | -0.3343 | -0.3343 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -23.84 | -41.75 | -25.56 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Galectin Therapeutics Inc | 0.00 | -44.81m | 203.66m | 14.00 | -- | -- | -- | -- | -0.7456 | -0.7456 | 0.00 | -0.9739 | 0.00 | -- | -- | 0.00 | -165.97 | -92.08 | -394.92 | -121.97 | -- | -- | -- | -- | -- | -12.72 | 6.24 | -- | -- | -- | -15.26 | -- | -- | -- |
| Design Therapeutics Inc | 0.00 | -66.86m | 206.20m | 58.00 | -- | 0.7423 | -- | -- | -1.19 | -1.19 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -21.20 | -- | -21.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -13.07m | 206.38m | 1.00 | -- | 58.00 | -- | -- | -0.48 | -0.48 | 0.00 | 0.1202 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.40 | 0.0285 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Lineage Cell Therapeutics Inc | 8.95m | -21.49m | 207.39m | 75.00 | -- | 3.04 | -- | 23.18 | -0.1243 | -0.1243 | 0.0518 | 0.3624 | 0.0796 | -- | 17.17 | 119,266.70 | -19.12 | -19.53 | -22.55 | -22.59 | 92.50 | 89.13 | -240.12 | -370.88 | -- | -- | 0.0023 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| Actinium Pharmaceuticals Inc | 81.00k | -48.82m | 207.54m | 49.00 | -- | 5.36 | -- | 2,562.21 | -1.84 | -1.84 | 0.0031 | 1.32 | 0.0008 | -- | -- | 1,653.06 | -49.91 | -46.98 | -55.31 | -52.71 | -- | -- | -60,269.14 | -6,683.95 | -- | -- | 0.0008 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| G1 Therapeutics Inc | 82.51m | -47.97m | 208.28m | 100.00 | -- | 5.86 | -- | 2.52 | -0.953 | -0.953 | 1.53 | 0.6815 | 0.5332 | 0.5028 | 6.94 | 825,110.00 | -31.00 | -47.06 | -39.28 | -52.64 | 91.28 | -- | -58.13 | -268.59 | 3.45 | -5.22 | 0.593 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Zura Bio Ltd | 0.00 | -69.24m | 210.79m | 14.00 | -- | 2.43 | -- | -- | -4.38 | -4.38 | 0.00 | 1.36 | 0.00 | -- | -- | 0.00 | -49.98 | -- | -60.56 | -- | -- | -- | -- | -- | -- | -- | 0.0123 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Adverum Biotechnologies Inc | 3.60m | -117.17m | 211.49m | 121.00 | -- | 1.24 | -- | 58.75 | -11.62 | -11.62 | 0.3571 | 8.23 | 0.015 | -- | -- | 29,752.07 | -48.68 | -36.39 | -55.24 | -39.04 | -- | -- | -3,254.58 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Prelude Therapeutics Inc | 0.00 | -121.83m | 212.54m | 128.00 | -- | 0.8964 | -- | -- | -2.05 | -2.05 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -48.91 | -47.21 | -53.60 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Merrimack Pharmaceuticals Inc | 0.00 | -1.18m | 213.76m | -- | -- | 11.26 | -- | -- | -0.0826 | -0.0826 | 0.00 | 1.31 | 0.00 | -- | -- | -- | -6.05 | -23.52 | -6.22 | -26.08 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.51 | -- | -- | -- |
| CervoMed Inc | 7.14m | -2.17m | 214.09m | 8.00 | -- | 18.92 | -- | 29.96 | -0.6282 | -0.6282 | 2.07 | 1.30 | 0.4382 | -- | -- | 893,108.80 | -13.32 | -53.67 | -15.74 | -58.89 | -- | -- | -30.40 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 0.00 | -101.17m | 216.64m | 93.00 | -- | 4.23 | -- | -- | -0.6026 | -0.6026 | 0.00 | 0.3052 | 0.00 | -- | -- | 0.00 | -66.81 | -61.53 | -78.53 | -69.20 | -- | -- | -- | -13,288.93 | -- | -- | 0.5164 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
Data as of Apr 25 2024. Currency figures normalised to Actinium Pharmaceuticals Inc's reporting currency: US Dollar USD
19.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.57m | 5.64% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.31m | 4.73% |
| District 2 Capital LPas of 31 Dec 2023 | 826.43k | 2.98% |
| Geode Capital Management LLCas of 31 Dec 2023 | 569.55k | 2.05% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 506.84k | 1.83% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 226.39k | 0.82% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 147.44k | 0.53% |
| Brandywine Global Investment Management LLCas of 31 Dec 2023 | 145.60k | 0.52% |
| Teachers Advisors LLCas of 31 Dec 2023 | 86.36k | 0.31% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 83.97k | 0.30% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
